VAXCYTE INC. DL -001
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrie… Read more
Market Cap & Net Worth: VAXCYTE INC. DL -001 (5VA)
VAXCYTE INC. DL -001 (F:5VA) has a market capitalization of $6.75 Billion (€6.57 Billion) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #2575 globally and #210 in its home market, demonstrating a -6.91% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying VAXCYTE INC. DL -001's stock price €45.80 by its total outstanding shares 143556263 (143.56 Million).
VAXCYTE INC. DL -001 Market Cap History: 2020 to 2026
VAXCYTE INC. DL -001's market capitalization history from 2020 to 2026. Data shows growth from $3.33 Billion to $6.75 Billion (0.77% CAGR).
VAXCYTE INC. DL -001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how VAXCYTE INC. DL -001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 5VA by Market Capitalization
Companies near VAXCYTE INC. DL -001 in the global market cap rankings as of March 19, 2026.
Key companies related to VAXCYTE INC. DL -001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
VAXCYTE INC. DL -001 Historical Marketcap From 2020 to 2026
Between 2020 and today, VAXCYTE INC. DL -001's market cap moved from $3.33 Billion to $ 6.75 Billion, with a yearly change of 0.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €6.75 Billion | +21.81% |
| 2025 | €5.54 Billion | -53.29% |
| 2024 | €11.86 Billion | +45.05% |
| 2023 | €8.18 Billion | +25.57% |
| 2022 | €6.51 Billion | +108.49% |
| 2021 | €3.12 Billion | -6.19% |
| 2020 | €3.33 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of VAXCYTE INC. DL -001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.75 Billion USD |
| MoneyControl | $6.75 Billion USD |
| MarketWatch | $6.75 Billion USD |
| marketcap.company | $6.75 Billion USD |
| Reuters | $6.75 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.